SCHEMBL1173409

SCHEMBL1173409

C/C=C/C=C/C(=O)OC(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.56
CA12 O43570 1/20 0.43
AKR1B10 O60218 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
AKR1B1 P15121 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
TSHR P16473 1/20 0.39
CNR2 P34972 4/20 0.37
CNR1 P21554 2/20 0.37
PPARG P37231 2/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
ALDH1A1 P00352 1/20 0.36
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1173410 1.00 HCAR2 (0.56) HCAR2CA12AKR1B10CA1CA2
SCHEMBL2946832 0.91 HCAR2 (0.65) HCAR2CA12AKR1B10CA1CA2
SCHEMBL2946831 0.91 HCAR2 (0.65) HCAR2CA12AKR1B10CA1CA2
SCHEMBL25867924 0.91 HCAR2 (0.65) HCAR2CA12AKR1B10CA1CA2
SCHEMBL4754373 0.86 HCAR2 (0.40) HCAR2CA12AKR1B10CA1CA2
SCHEMBL4754376 0.86 HCAR2 (0.40) HCAR2CA12AKR1B10CA1CA2
SCHEMBL27771869 0.84 HCAR2 (0.39) HCAR2CA12AKR1B10CA1CA2
SCHEMBL27771867 0.84 HCAR2 (0.39) HCAR2CA12AKR1B10CA1CA2
SCHEMBL7472279 0.84 HCAR2 (0.58) HCAR2CA12AKR1B10CA1CA2
SCHEMBL7472276 0.84 HCAR2 (0.58) HCAR2CA12AKR1B10CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119432125-A Chitosan black talc compound for mildew prevention and antibacterial of rubber cable and preparation and application thereof 浙江工业大学 2025-02-14 CN claimed
CN-118772350-A Nanometer oil displacement agent for high-temperature high-salt oil field and preparation method thereof 河南正佳能源环保股份有限公司 2024-10-15 CN claimed
US-20230363380-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2023-11-16 US claimed
US-20220079145-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2022-03-17 US claimed
US-20180077925-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2018-03-22 US claimed
EP-3265135-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF Wilson, John Paul (US) 2018-01-10 EP claimed
EP-1729768-B1 IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS MEDA AB (SE) 2018-01-10 EP claimed
WO-2016144907-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2016-09-15 WO claimed
WO-2013042019-A1 PROCESS FOR PREPARING MANUFACTURED PRODUCTS IN CONGLOMERATE OF GRANULATE OF STONE MATERIAL AND RESIN WITH ANHYDRIDES FROM RENEWABLE SOURCES TONCELLI LUCA (IT) 2013-03-28 WO claimed
EP-1613302-B1 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORP (US) 2009-12-23 EP claimed
US-20070167479-A1 Immune response modifier formulations and methods BAUSCH HEALTH COMPANIES INC. (CA) 2007-07-19 US claimed
EP-1729768-A2 IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS 3M Innovative Properties Company (US) 2006-12-13 EP claimed
US-7128923-B2 Preserved and stable compositions containing peptide copper complexes and method related thereto PROCYTE CORPORATION (US) 2006-10-31 US claimed
WO-2006099275-A2 METHOD OF TREATING ACTINIC KERATOSIS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-09-21 WO claimed
WO-2005089317-A2 IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-09-29 WO claimed
EP-0705094-B1 SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS CARSON PROD CO (US) 2000-05-24 EP claimed
EP-0705094-A4 SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS AMINCO INC (US) 1996-08-07 EP claimed
EP-0705094-A1 SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS CARSON PRODUCTS COMPANY (US) 1996-04-10 EP claimed
WO-1995000107-A1 SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS AMINCO, INC. (US) 1995-01-05 WO claimed
EP-0224981-A2 Nitroglycerin transdermal delivery system PACO RESEARCH CORPORATION (US) 1987-06-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167479-A1 Immune response modifier formulations and methods IFNG, TLR5, ICOS HCAR2 288/4885CA12 3454/4885AKR1B10 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.